Related content

Pharmacogenomic considerations of the paraoxonase polymorphisms

By Furlong Clement E   Cole Toby B   Jarvik Gail P   Costa Lucio G  

Pharmacogenomics, Vol. 3, Iss. 3, 2002-05 ,pp. : 341-348

Future Medicine

Access to resources Recommend Favorite

The stress-induced anhedonia model of depression predicts antidepressant-like properties of the COMT inhibitor tolcapone

By Moreau J.-L.   Jenck F.   Martin J.R.   Mutel V.   Da Prada M.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 168-168

Elsevier

Access to resources Recommend Favorite

Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations

By Baudin Bruno  

Pharmacogenomics, Vol. 3, Iss. 1, 2002-01 ,pp. : 65-73

Future Medicine

Access to resources Recommend Favorite

Targeting Catechol-O-Methyl Transferase (COMT) Inhibitors for Schizophrenia:An Approach to Target Validation and Rational Drug Design

By  

Letters in Drug Design & Discovery, Vol. 8, Iss. 3, 2011-03 ,pp. : 246-252

Bentham Science Publishers

Access to resources Recommend Favorite

Dopamine receptor polymorphisms and drug response in schizophrenia

By Scharfetter Joachim  

Pharmacogenomics, Vol. 2, Iss. 3, 2001-08 ,pp. : 251-261

Future Medicine

Access to resources Recommend Favorite